Module 5clinicalnda● High priority
5.3.4.2 — Patient PD and PK/PD Reports
PD and PK/PD studies in patients including dose-response characterization
Requirements by Phase
Phase 1
N/A
Phase 2
protocol
Phase 3
report
NDA
required
PD and PK/PD studies in patients including dose-response characterization
Requirements by Phase
IND Phase 2: protocol IND Phase 3: report NDA: required
Content Requirements
- PD and PK/PD studies in patients
- Dose-response characterization
- Exposure-response analysis
- Full CSR per ICH E3 format
Expected Deliverables
- Patient PD study report (ICH E3 format)
- Exposure-response analysis report
ICH Guidelines: E3, E4, M4E(R2)
Source: ICH E4; ICH E3
Related Sections
Up to5.3 — Clinical Study Reports5.3.1 — Reports of Biopharmaceutic Studies
5.3.1.1 — Bioavailability Study Reports
Reports of absolute and relative bioavailability studies
5.3.1.2 — Comparative BA/BE Study Reports
Reports of comparative bioavailability and bioequivalence studies
5.3.1.3 — In Vitro–In Vivo Correlation Reports
Reports correlating in vitro dissolution to in vivo bioavailability
5.3.1.4 — Bioanalytical and Analytical Methods
Validation reports for bioanalytical methods used in human studies
+19 more sections
Check your compliance against this section
Upload your study data and get instant gap analysis with specific regulatory citations.
Try Compliance Check